This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping high normal patients from progressing to illness. People in this study cannot have diabetes but are considered "borderline" based on blood tests. People in the study take one or both of the drugs and do not know which one(s) they are taking.

Condition	Treatment or Intervention	Phase
Diabetes Mellitus, Type 2	Drug: Diovan (valsartan)  Drug: Starlix (nateglinide)	Phase III

Further Study Details: 

Primary Outcomes: The number of heart attacks and number of deaths due to heart disease and number developing diabetes.
Expected Total Enrollment:  9150

Ages Eligible for Study:  50 Years   -   75 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Adults
• Impaired glucose tolerance
• Age dependent risk factors

Exclusion Criteria:

• Frank diabetes

For detailed information, call contact person.

Study ID Numbers:  CDJN608B2302
Record last reviewed:  November 2004
Last Updated:  November 30, 2004
Record first received:  November 30, 2004
ClinicalTrials.gov Identifier:  NCT00097786
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08